OC9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Stronger Balance Sheet And Lower LeverageOmnicell materially reduced leverage (debt-to-equity down to ~0.17) and repaid a $175M obligation, lowering financial risk and increasing capital flexibility. This durable improvement supports investment in product rollouts and reduces refinancing pressure over the next several quarters.
Consistent Free Cash Flow GenerationHealthy operating cash flow (~$156M TTM) and rising free cash flow (~$112M, +32%) show the business converts revenue into cash. Durable cash generation underpins R&D, service deployment, and capital allocation without heavy reliance on external funding across the next 2–6 months.
Product Launches And Strengthened Commercial TractionNew hardware (Titan XT) and cloud platform (OmniSphere), plus initial orders and maintained ARR/bookings targets, indicate durable product-driven growth potential. These innovations expand addressable market, deepen customer lock‑in via software/services, and support recurring revenue over multiple quarters.
Bears Say
Very Thin Net Margin And Low ROEDespite revenue recovery, Omnicell's bottom‑line profitability is minimal (net margin ~0.2%) and ROE is weak. This limited earnings power constrains retained earnings for reinvestment and makes sustained margin improvement essential to convert gross margin strength into lasting shareholder returns.
Titan XT Adoption Pacing UncertaintyTitan XT revenue is expected to be back‑end weighted because hospital capital approval cycles are long. That structural timing risk reduces near‑term visibility into product-driven growth and can delay conversion of strong pipeline into recognized revenue and ARR over several quarters.
Tariff-related Cost Headwind And Margin PressureManagement explicitly built a ~$12M tariff cost headwind into 2026 guidance. Persistent or increasing tariffs create structural cost pressure on gross margins, reducing earnings leverage from existing revenue and making margin recovery more contingent on pricing, mix, or cost mitigation over the medium term.
Omnicell News
OC9 FAQ
What was Omnicell’s price range in the past 12 months?
Currently, no data Available
What is Omnicell’s market cap?
Omnicell’s market cap is CHF1.65B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Apr 28, 2026. The company reported $0.442 earnings per share for the quarter, beating the consensus estimate of $0.266 by $0.176.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.38.
How many shares outstanding does Omnicell have?
Currently, no data Available
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.442 in its last earnings report, beating expectations of $0.266. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in CH:OC9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Omnicell Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF52.48 (― Downside)
CHF52.48 (― Downside)
Blogger Sentiment
Bullish
CH:OC9 Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.12%
12-Months-Change
Fundamentals
Return on Equity
1.64%
Trailing 12-Months
Asset Growth
-6.85%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
OC9 Company Deck
OC9 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust top-line growth (+15% YoY), outsized improvement in profitability (non-GAAP EBITDA and EPS nearly doubling year-over-year), improved free cash flow, and constructive commercial traction following the Titan XT and OmniSphere launches. Management raised FY profitability guidance while maintaining revenue and bookings targets. Key risks discussed include near-term pacing of Titan XT adoption due to long capital cycles, a $12M tariff headwind, a lower cash balance after debt repayment and buybacks, and some potential quarter-to-quarter margin/revenue variability as expenses are phased throughout the year. On balance, positive execution, raised guidance, and a strong pipeline outweigh the timing and macro/cyclical headwinds.View all CH:OC9 earnings summariesOC9 Stock 12 Month Forecast
Average Price Target
$52.48
Options Prices
Currently, No data available
---